Technical Analysis for QURE - uniQure N.V.

Grade Last Price % Change Price Change
D 4.69 -4.09% -0.20
QURE closed down 4.09 percent on Monday, June 17, 2024, on 74 percent of normal volume.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Down 3 Days in a Row Weakness 0.00%
Fell Below 20 DMA Bearish -4.09%
Fell Below 50 DMA Bearish -4.09%
MACD Bearish Signal Line Cross Bearish -4.09%
NR7 Range Contraction -10.67%
Gapped Up Strength -11.17%
Calm After Storm Range Contraction -10.33%
Calm After Storm Range Contraction -12.83%
180 Bullish Setup Bullish Swing Setup -12.01%
Calm After Storm Range Contraction -12.01%

   Recent Intraday Alerts

Alert Time
Down 3% about 6 hours ago
60 Minute Opening Range Breakdown about 7 hours ago
Down 2 % about 8 hours ago
Fell Below Previous Day's Low about 8 hours ago
Down 1% about 8 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

uniQure N.V. Description

uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Disease Clinical Development Genetics Gene Therapy Parkinson's Disease Metabolic Disease Applied Genetics Gene Delivery Lipoprotein Hemophilia Adeno Associated Virus Treatment Of Hemophilia Acute Intermittent Porphyria Alipogene Tiparvovec Glybera Lipase Lipoprotein Lipase Deficiency

Is QURE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.25
52 Week Low 4.25
Average Volume 582,572
200-Day Moving Average 5.98
50-Day Moving Average 4.90
20-Day Moving Average 5.04
10-Day Moving Average 5.22
Average True Range 0.27
RSI (14) 39.02
ADX 20.91
+DI 20.47
-DI 25.15
Chandelier Exit (Long, 3 ATRs) 4.81
Chandelier Exit (Short, 3 ATRs) 5.33
Upper Bollinger Bands 5.60
Lower Bollinger Band 4.48
Percent B (%b) 0.19
BandWidth 22.31
MACD Line 0.04
MACD Signal Line 0.08
MACD Histogram -0.0403
Fundamentals Value
Market Cap 224.24 Million
Num Shares 47.8 Million
EPS -4.79
Price-to-Earnings (P/E) Ratio -0.98
Price-to-Sales 2.53
Price-to-Book 1.05
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.05
Resistance 3 (R3) 5.08 4.98 4.99
Resistance 2 (R2) 4.98 4.89 4.97 4.97
Resistance 1 (R1) 4.84 4.84 4.79 4.81 4.95
Pivot Point 4.74 4.74 4.72 4.73 4.74
Support 1 (S1) 4.60 4.65 4.55 4.57 4.43
Support 2 (S2) 4.50 4.60 4.49 4.41
Support 3 (S3) 4.36 4.50 4.39
Support 4 (S4) 4.33